Niccolo Bartalucci

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia.

Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: March 16, 2026

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 16, 2025

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

Journal: American journal of hematology

Published: August 14, 2025

Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.

Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.

Journal: Leukemia

Published: July 23, 2025

Correction: Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.

Correction: Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.

Journal: Leukemia

Published: April 01, 2025

A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.

A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.

Journal: Leukemia

Published: February 04, 2025

CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.

CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.

Journal: Journal of cellular and molecular medicine

Published: January 30, 2025

Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms.

Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms.

Journal: Leukemia

Published: January 22, 2024

Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.

Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.

Journal: Leukemia

Published: January 18, 2024

Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.

Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.

Journal: American journal of hematology

Published: June 13, 2023

Resolving complex structural variants via nanopore sequencing.

Resolving complex structural variants via nanopore sequencing.

Journal: Frontiers in genetics

Published: April 28, 2023

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.

Journal: Leukemia

Published: November 23, 2022

Showing 1-12 of 51

Last Updated: 09/26/2026